Source: Annual Congress 2004 - Cystic fibrosis: the expanding clinical issues



Rating:

Share or cite this content

Citations should be made in the following way:
D. Zemkova, P. Drevinek, V. Vavrova, P. Pohunek (Prague, Czech Republic). Early diagnostics of Burkholderia cenocepacia improves survival rate in patients with cystic fibrosis. Eur Respir J 2004; 24: Suppl. 48, 3759

Member's Comments

No comment yet.

Related content which might interest you: Survival outcomes following lung transplantation for cystic fibrosis patients infected with Burkholderia cenocepacia Source: Annual Congress 2007 - New insights into clinical lung transplantation Year: 2007 Burkholderia cepacia infection in adult cystic fibrosis patients: Its impact on lung function and survival Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients Source: Eur Respir J 2004; 23: 851-856 Year: 2004 Treatment of Burholderia cepacia infection in patients with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 539s Year: 2001 Burkholderia cepacia complex infection in Czech patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Changes in local and systemic inflammatory markers in cystic fibrosis patients chronically infected with Burkholderia cepacia complex Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Does sputum induction improve Pseudomonas aeruginosa detection in cystic fibrosis? Source: Eur Respir J 2003; 22: Suppl. 45, 231s Year: 2003 Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients Source: Eur Respir J 2001; 17: 36-38 Year: 2001 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021 Taurolidine in the management of lung transplant recipients with cystic fibrosis colonized with burkholderia cepacia Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002 Detection of Pseudomonas aeruginosa infection in cystic fibrosis patients by eNose technology Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Long-term evaluation of the response to aggressive treatment at the first colonization of P.aeruginosa in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Predictors of eradication failure at first isolation of MRSA in cystic fibrosis patients Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Isolation of Achromobacter xylosoxidans from the respiratory secretions of patients with cystic fibrosis: frequency in the population and significance to the progression of lung disease Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005 Host specificity of pseudomonas aeruginosa isolates from patients with cystic fibrosis and patients from different clinical backgrounds Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis Source: Eur Respir J 2015; 46: 862-865 Year: 2015